Latest market price
9.79
-0.47-4.58%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -3.37 | Insider Own | 11.66% | Shs Outstand | 88.96M | Perf Week | 1.77% |
| Market Cap | 870.92M | Forward P/E | — | EPS next Y | -2.42 | Insider Trans | -0.52% | Shs Float | 86.49M | Perf Month | -8.08% |
| Enterprise Value | 374.92M | PEG | — | EPS next Q | -0.82 | Short Float | 16.56% | Perf Quarter | 3.38% | ||
| Income | -296.00M | P/S | 11.31 | EPS this Y | — | Short Ratio | 7.85 | Perf Half Y | 5.84% | ||
| Sales | 77.00M | P/B | 18.14 | EPS next Y | — | ROA | -50.49% | Short Interest | 14.32M | Perf YTD | -5.77% |
| Book/sh | 0.54 | P/C | 1.68 | EPS next 5Y | — | ROE | -207.18% | 52W High | 13.90 -29.57% | Perf Year | -6.23% |
| Cash/sh | 5.83 | P/FCF | — | EPS past 3/5Y | — | ROIC | -66.95% | 52W Low | 7.36 33.02% | Perf 3Y | 23.92% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 94.73% | Volatility | 6.43% 5.08% | Perf 5Y | -43.67% |
| Dividend TTM | — | EV/Sales | 4.87 | EPS Y/Y TTM | — | Oper. Margin | -411.90% | ATR (14) | 0.54 | Perf 10Y | 81.30% |
| Dividend Ex-Date | — | Quick Ratio | 4.71 | Sales Y/Y TTM | -7.23% | Profit Margin | -384.30% | RSI (14) | 43.14 | Recom | 2.12 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.73 | EPS Q/Q | -2.67% | SMA20 | -2.33% | Beta | 0.53 | Target Price | 24.00 |
| Payout | 0.00% | Debt/Eq | 0.48 | Sales Q/Q | 40.00% | SMA50 | -11.89% | Rel Volume | 0.90 | Prev Close | 10.26 |
| Employees | 260 | LT Debt/Eq | 0.40 | Earnings | Nov 03 | SMA200 | -0.21% | Avg Volume | 1.92M | Price | 9.79 |
| IPO Date | Sep 16, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.23% 3.53% | Net Debt/EBITDA | — | Volume | 1,723,145 | Change | -4.58% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-14-26 | Reiterated | Deutsche Bank | $24 | |
| Oct-14-26 | Reiterated | Barclays | Overweight | $28 → $24 |
| Aug-24-26 | Reiterated | Morgan Stanley | $24 | |
| Aug-24-26 | Reiterated | Raymond James | $24 | |
| Jun-15-26 | Reiterated | Bernstein | $24 | |
| Jun-04-26 | Reiterated | CLSA | $24 | |
| Jun-04-26 | Reiterated | Wells Fargo | $24 | |
| May-28-26 | Reiterated | Oppenheimer | Outperform | $24 |
| May-28-26 | Reiterated | Jefferies | Buy | $24 |
| Apr-14-26 | Initiated | Lake Street | Buy | $23 |
Latest News· Times ET
Oct-28-26
Oct-28-2609:00AM
Oct-27-26
Oct-27-2611:06AM
Oct-13-26
Oct-13-2608:02PM
07:52PM
07:30AM
Oct-07-26
Oct-07-2607:15AM
Oct-02-26
Oct-02-2607:30AM
Oct-01-26
Oct-01-2608:03AM
Sep-29-26
Sep-29-2605:15AM
Sep-26-26
Sep-26-2604:34AM
Sep-17-26
Sep-16-26
Sep-16-2601:51PM
Sep-09-26
Sep-09-2607:00AM
Company
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 77 | 67 | 54 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4 | 0 | 0 | 1 | — | — | — | — | — | |
| Gross Profit | 74 | 67 | 54 | -1 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 135 | 120 | 77 | 51 | — | — | — | — | — | |
| Research and Development | 259 | 251 | 170 | 115 | — | — | — | — | — | |
| Other Operating Expense | -2 | 0 | 0 | -1 | — | — | — | — | — | |
| Operating Income | -318 | -304 | -193 | -166 | — | — | — | — | — | |
| Interest Expense | 0 | 2 | 2 | 2 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 23 | 27 | 23 | 15 | — | — | — | — | — | |
| Net Income Before Taxes | -296 | -278 | -172 | -153 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 2 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -296 | -279 | -174 | -153 | — | — | — | — | — | |
| Net Income From Continuing Operations | -296 | -279 | -174 | -153 | — | — | — | — | — | |
| Net Income | -296 | -279 | -174 | -153 | — | — | — | — | — | |
| EPS (Recurring) | -3.37 | -3.18 | -2.02 | -2.08 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.37 | -3.18 | -2.02 | -2.08 | — | — | — | — | — | |
| EPS (Diluted) | -3.37 | -3.18 | -2.02 | -2.08 | — | — | — | — | — | |
| EBITDA | -295 | -276 | -169 | -150 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 11.32 | 13.65 | 13.87 | — | — | — | — | — | — | |
| Gross Margin | 96.10 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -412.99 | -453.73 | -357.41 | — | — | — | — | — | — | |
| Net Margin | -384.42 | -416.42 | -322.22 | — | — | — | — | — | — | |
| Shares Outstanding | 89 | 88 | 86 | 73 | — | — | — | — | — | |
| Market Capitalization | 871 | 914 | 749 | 1,050 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| FORD KATHLEEN | Chief Operating Officer | Sep 29 '26 | Sale | 10.75 | 3,668 | 39,437 | 142,986 | Sep 29 |
| Leoni Mollie | Chief Medical Officer | Sep 29 '26 | Sale | 10.75 | 28,802 | 309,567 | 141,095 | Sep 29 |
| Powl Brian T. | Chief Commercial Officer | Sep 29 '26 | Sale | 10.75 | 15,430 | 165,852 | 136,819 | Sep 29 |
| Leoni Mollie | Chief Medical Officer | Sep 28 '26 | Sale | 10.50 | 12,448 | 130,670 | 169,897 | Sep 29 |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sep 28 '26 | Sale | 10.50 | 4,607 | 48,361 | 142,428 | Sep 29 |
| Bair Teresa Brophy | Chief Legal Officer | Sep 28 '26 | Sale | 10.50 | 8,442 | 88,618 | 187,002 | Sep 29 |
| Powl Brian T. | Chief Commercial Officer | Sep 28 '26 | Sale | 10.53 | 17,020 | 179,184 | 152,249 | Sep 29 |
| FORD KATHLEEN | Chief Operating Officer | Sep 28 '26 | Sale | 10.50 | 6,906 | 72,494 | 146,654 | Sep 29 |
| Burrows Francis | Chief Scientific Officer | Sep 24 '26 | Option Exercise | 6.15 | 30,000 | 184,500 | 63,053 | Sep 25 |
| Burrows Francis | Chief Scientific Officer | Sep 24 '26 | Sale | 10.83 | 20,726 | 224,514 | 42,327 | Sep 25 |
| WILSON TROY EDWARD | President and CEO | Aug 24 '26 | Buy | 12.39 | 100,000 | 1,239,000 | 479,194 | Aug 24 |
| Powl Brian T. | Chief Commercial Officer | Aug 21 '26 | Sale | 11.89 | 4,345 | 51,663 | 169,269 | Aug 24 |
| Bair Teresa Brophy | Chief Legal Officer | Aug 19 '26 | Sale | 12.63 | 31,487 | 397,681 | 195,444 | Aug 21 |
| WILSON TROY EDWARD | President and CEO | Aug 17 '26 | Buy | 11.12 | 100,000 | 1,112,000 | 379,194 | Aug 17 |
| Leoni Mollie | Chief Medical Officer | Jun 18 '26 | Sale | 9.82 | 84,929 | 834,283 | 182,345 | Jun 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.